Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors.

Marcu-Malina V, van Dorp S, Kuball J.

Expert Opin Biol Ther. 2009 May;9(5):579-91. doi: 10.1517/14712590902887018 . Review.

PMID:
19368527
2.

T-cell engineering for cancer immunotherapy.

Sadelain M.

Cancer J. 2009 Nov-Dec;15(6):451-5. doi: 10.1097/PPO.0b013e3181c51f37. Review.

PMID:
20010162
3.

Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy.

Engels B, Uckert W.

Mol Aspects Med. 2007 Feb;28(1):115-42. Epub 2007 Jan 11. Review.

PMID:
17307249
4.

Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.

Berry LJ, Moeller M, Darcy PK.

Tissue Antigens. 2009 Oct;74(4):277-89. doi: 10.1111/j.1399-0039.2009.01336.x. Review.

PMID:
19775368
5.

Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.

Altenschmidt U, Klundt E, Groner B.

J Immunol. 1997 Dec 1;159(11):5509-15.

PMID:
9548491
6.

Generation of tumor-specific T-cell therapies.

Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H.

Blood Rev. 2006 Mar;20(2):61-9. Epub 2005 Jun 22. Review.

PMID:
15978709
7.

Genetic engineering of T cell specificity for immunotherapy of cancer.

Willemsen RA, Debets R, Chames P, Bolhuis RL.

Hum Immunol. 2003 Jan;64(1):56-68. Review.

PMID:
12507815
8.

T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.

Schaft N, Lankiewicz B, Drexhage J, Berrevoets C, Moss DJ, Levitsky V, Bonneville M, Lee SP, McMichael AJ, Gratama JW, Bolhuis RL, Willemsen R, Debets R.

Int Immunol. 2006 Apr;18(4):591-601. Epub 2006 Feb 28.

PMID:
16507598
9.

Long-term functionality of TCR-transduced T cells in vivo.

Coccoris M, Swart E, de Witte MA, van Heijst JW, Haanen JB, Schepers K, Schumacher TN.

J Immunol. 2008 May 15;180(10):6536-43.

10.

A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer.

Kieback E, Charo J, Sommermeyer D, Blankenstein T, Uckert W.

Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):623-8. doi: 10.1073/pnas.0710198105. Epub 2008 Jan 8.

11.

Prospects and limitations of T cell receptor gene therapy.

Jorritsma A, Schotte R, Coccoris M, de Witte MA, Schumacher TN.

Curr Gene Ther. 2011 Aug;11(4):276-87. Review.

PMID:
21453279
12.

Breast cancer immunotherapy.

Zhou J, Zhong Y.

Cell Mol Immunol. 2004 Aug;1(4):247-55. Review.

13.

Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases.

Sheen AJ, Irlam J, Kirillova N, Guest RD, Sherlock DJ, Hawkins RE, Gilham DE.

Dis Colon Rectum. 2003 Jun;46(6):793-804.

PMID:
12794582
14.

Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.

Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, Wakita D, Azuma T, Niiya H, Miyoshi H, Kuzushima K, Oka Y, Sugiyama H, Ikeda H, Nishimura T.

Blood. 2005 Jul 15;106(2):470-6. Epub 2005 Mar 24.

15.

T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.

Bobisse S, Zanovello P, Rosato A.

Expert Opin Biol Ther. 2007 Jun;7(6):893-906. Review.

PMID:
17555374
16.

Gene transfer of MHC-restricted receptors.

Kessels HW, Wolkers MC, Schumacher TN.

Methods Mol Med. 2005;109:201-14.

PMID:
15585923
17.

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, Smyth FE, Cartwright GA, Power BE, Hönemann D, Prince HM, Darcy PK, Kershaw MH.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19051-6. Epub 2005 Dec 19.

18.

Preclinical development of T cell receptor gene therapy.

Bendle GM, Haanen JB, Schumacher TN.

Curr Opin Immunol. 2009 Apr;21(2):209-14. doi: 10.1016/j.coi.2009.02.007. Epub 2009 Mar 25. Review.

PMID:
19321326
19.

Requirements for effective antitumor responses of TCR transduced T cells.

de Witte MA, Jorritsma A, Kaiser A, van den Boom MD, Dokter M, Bendle GM, Haanen JB, Schumacher TN.

J Immunol. 2008 Oct 1;181(7):5128-36.

20.

Chimeric T-cell receptors for the targeting of cancer cells.

Rössig C, Brenner MK.

Acta Haematol. 2003;110(2-3):154-9. Review.

PMID:
14583676

Supplemental Content

Support Center